7:02AM ISIS Pharm publishes data demonstrating antisense targeting of ApoC-III significantly reduces ApoC-III and Triglycerides (ISIS) 16.94 : Co announced today the publication of new data in the journal Circulation Research demonstrating that antisense targeting of apolipoprotein C-III resulted in significant reductions in apoC-III and triglycerides, each an independent risk factor for cardiovascular disease. Hypertriglyceridemia is a serious medical condition associated with premature coronary artery disease and an increased risk for pancreatitis.
In the published data, treatment with an antisense compound targeting apoC-III produced a variety of potential cardio-protective effects including significant dose-dependent reductions of apoC-III and triglycerides in all models and species, including man.
Market Data 
Markets 
AI
